Mass spectrometry reimagined for smarter, faster drug discovery
What is native mass spectrometry?
Native mass spectrometry is a powerful analytical approach for detecting molecular interactions under conditions that preserve biologically relevant complexes.
nMS sees what other methods don’t
It works directly in native samples, with no assay development, label-free, and without protein immobilisation.
This allows discovery teams to move faster, reduce risk and uncover interactions that might otherwise go undetected.
Our discovery platform
The fastest path through chemical space
CARMS accelerates drug screening into three key steps, all happening within a single instrument
How is native mass spectrometry different?
We don’t work around complexity, we cut through it.
Traditional hit identification often depends on purified proteins, custom assay development, and proxy readouts that can move discovery away from real biological context.
These steps can be slow, costly, and can miss interactions that matter.
nMS gives discovery teams a direct way to observe molecular interactions, helping identify promising binders while preserving the biological complexity that shapes real drug–target behaviour.
What only nMS can do
Label free
nMS works with untagged proteins in solution, eliminating the need for immobilisation or proxy readouts
Built-in filtering eliminates false positives
Selective mass detection ensures only true binders are captured.
No custom assays required
There is no need to build custom assays — binding is directly detected using mass spectrometry
High-throughput, even in complex samples
Highly multiplexed screening in lysates and mixtures without compromising biological fidelity.
Captures biological context
Go beyond binary target–ligand interactions — nMS captures the full complex, including all subunits and co-factors.
Delivers results in weeks, not months
By skipping purification and assay setup, CARMS dramatically reduces early-stage timelines.
Multi-stage nMS confirms true binding
Complexes are dissociated using controlled energy, observing and confirming each component
See real interactions. Prioritise the right hits.
Native mass spectrometry services
MassAffinity supports your early discovery needs.
We offer multiple native mass spectrometry workflows, from target–ligand characterisation to screening
How our technology supports the drug discovery pipeline?
The starting point for smarter drug discovery
MassAffinity targets the earliest phase of drug discovery, where many programs stall due to undruggable targets, assay limitations or biological complexity.